Home › Linfoma di Burkitt › Ohio
Studi clinici su Linfoma di Burkitt nello stato di Ohio
17 studi su Linfoma di Burkitt cercano partecipanti presso sedi nello stato di Ohio.
Città nello stato di Ohio
Testo ufficiale dello studio (inglese)
A Study Testing the Combination of Dasatinib or Imatinib to Chemotherapy Treatment With Blinatumomab for Children, Adolescents, and Young Adults With Philadelphia Chromosome Positive (Ph+) or ABL-Class Philadelphia Chromosome-Like (Ph-Like) B-cell Acute Lymphoblastic Leukemia (B-ALL)
- Children's Hospital Medical Center of Akron, Akron
- Cincinnati Children's Hospital Medical Center, Cincinnati
- Rainbow Babies and Childrens Hospital, Cleveland
- e altri 3
In reclutamentoFase 2
366 Days – 46 Years · Tutti i sessi · Aggiornato il 2 ott 2026 · NCT06124157Inotuzumab Ozogamicin and Frontline Chemotherapy in Treating Young Adults With Newly Diagnosed B Acute Lymphoblastic Leukemia
- University of Cincinnati Cancer Center-UC Medical Center, Cincinnati
- Case Western Reserve University, Cleveland
- Cleveland Clinic Foundation, Cleveland
- e altri 2
In reclutamentoFase 3
Età da 18 a 39 · Tutti i sessi · Aggiornato il 2 ott 2026 · NCT03150693Pharmacokinetic Study of Venetoclax Tablets Crushed and Dissolved Into a Solution
- Cincinnati Children's Hospital Medical Center, Cincinnati
In reclutamentoStudio osservazionale
Età da 0 a 38 · Tutti i sessi · Aggiornato il 1 ott 2026 · NCT06131801Inotuzumab Ozogamicin and Blinatumomab With or Without Ponatinib in Treating Patients With Newly Diagnosed, Recurrent, or Refractory CD22-Positive B-Lineage Acute Lymphoblastic Leukemia
- University of Cincinnati Cancer Center-UC Medical Center, Cincinnati
- Ohio State University Comprehensive Cancer Center, Columbus
- University of Cincinnati Cancer Center-West Chester, West Chester
In reclutamentoFase 2
Età 18 e oltre · Tutti i sessi · Aggiornato il 29 set 2026 · NCT03739814Testing the Addition of the Anti-cancer Drug Venetoclax and/or the Anti-cancer Immunotherapy Blinatumomab to the Usual Chemotherapy Treatment for Infants With Newly Diagnosed KMT2A-rearranged or KMT2A-non-rearranged Leukemia
- Children's Hospital Medical Center of Akron, Akron
- Cincinnati Children's Hospital Medical Center, Cincinnati
- Rainbow Babies and Childrens Hospital, Cleveland
- e altri 2
In reclutamentoFase 2
365 Days · Tutti i sessi · Aggiornato il 25 set 2026 · NCT06317662Single-arm Study of IgPro20 in Adults With Secondary Immune Deficiencies Due to Hematologic Malignancies Treated With B-cell Targeting Chimeric Antigen Receptor T-cell and T-cell Redirecting Therapies
- University of Cincinnati Medical Center, Cincinnati
In reclutamentoFase 3
Età 18 e oltre · Tutti i sessi · Aggiornato il 21 set 2026 · NCT07648264A Study of Fludarabine Dosing in Children and Young Adults With B-cell Acute Lymphoblastic Leukemia
- Cincinnati Children's Hospital Medical Center (Data Collection Only), Cincinnati
In reclutamentoFase 3
Età 1 e oltre · Tutti i sessi · Aggiornato il 17 set 2026 · NCT07223021A Study to Compare Blinatumomab Alone to Blinatumomab With Nivolumab in Patients Diagnosed With First Relapse B-Cell Acute Lymphoblastic Leukemia (B-ALL)
- Children's Hospital Medical Center of Akron, Akron
- Cincinnati Children's Hospital Medical Center, Cincinnati
- Rainbow Babies and Childrens Hospital, Cleveland
- e altri 3
In reclutamentoFase 2
Età da 1 a 30 · Tutti i sessi · Aggiornato il 1 set 2026 · NCT04546399Inotuzumab Ozogamicin and Post-Induction Chemotherapy in Treating Patients With High-Risk B-ALL, Mixed Phenotype Acute Leukemia, and B-LLy
- Children's Hospital Medical Center of Akron, Akron
- Cincinnati Children's Hospital Medical Center, Cincinnati
- Rainbow Babies and Childrens Hospital, Cleveland
- e altri 4
In reclutamentoFase 3
365 Days – 25 Years · Tutti i sessi · Aggiornato il 25 ago 2026 · NCT03959085Caloric Restriction and Activity to Reduce Chemoresistance in B-ALL
- Cincinnati Children's Hospital Medical Center, Cincinnati
In reclutamentoFase 2
Età da 7 a 25 · Tutti i sessi · Aggiornato il 19 ago 2026 · NCT05082519Gene Therapy for CD19-Positive Hematologic Malignancies (SENTRY-CD19)
- The Ohio State University Wexner Medical Center, Columbus
In reclutamentoFase 1/2
Età da 13 a 90 · Tutti i sessi · Aggiornato il 6 ago 2026 · NCT06533579Genetically Engineered Cells (Anti-CD19/CD20/CD22 CAR T-cells) for the Treatment of Relapsed or Refractory Lymphoid Malignancies
- Nationwide Children's Hospital, Columbus
- Ohio State University Comprehensive Cancer Center, Columbus
In reclutamentoFase 1
Età 2 e oltre · Tutti i sessi · Aggiornato il 29 mag 2026 · NCT05418088Asparaginase Erwinia Chrysanthemi With Chemotherapy for the Treatment of High-Risk Adults With Newly Diagnosed Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma
- Cleveland Clinic Foundation, Cleveland
In reclutamentoFase 2
Età da 18 a 54 · Tutti i sessi · Aggiornato il 17 mar 2026 · NCT06918431Study of Inotuzumab Ozogamicin, Venetoclax, and Dexamethasone for Relapsed B-cell ALL
- Cincinnati Children's Hospital Medical Center, Cincinnati
In reclutamentoFase 1
Età da 1 a 39 · Tutti i sessi · Aggiornato il 18 feb 2026 · NCT06863259Study of SGR-1505 in Mature B-Cell Neoplasms
- Gabrail Cancer & Research Center, Canton
- The Ohio State University - The James Cancer Hospital, Columbus
In reclutamentoFase 1
Età 18 e oltre · Tutti i sessi · Aggiornato il 13 feb 2026 · NCT05544019Study of HQP1351 in Subjects With Refractory CML and Ph+ ALL
- Cleveland Clinic, Cleveland
In reclutamentoFase 1
Età 18 e oltre · Tutti i sessi · Aggiornato il 5 nov 2025 · NCT04260022Study of VIP943 in Subjects With Advanced CD123+ Hematologic Malignancies
- University of Cincinnati, Cincinnati
In reclutamentoFase 1
Età 18 e oltre · Tutti i sessi · Aggiornato il 15 nov 2024 · NCT06034275Fonte: ClinicalTrials.gov, dati recuperati il 5 ott 2026. Ogni studio stabilisce i propri criteri di idoneità; è il team di ricerca a decidere chi può partecipare.